Akums Drugs shares rose sharply on Monday to hit a 52-week high after the company reported strong Q1 FY27 results. Revenue rose 13.9% year-on-year, while profit increased 55%. EBITDA grew 35.4%, supported by strong performance in its CDMO business. The stock has gained 67% so far this year.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.